
Håvard Midgard
- Resident; MD, PhD
- +47 908 30 071
Education:
- MD University of Oslo (2007)
- PhD University of Oslo (2017)
Current position:
Resident, Department of Gastroenterology, Oslo University Hospital
Publications 2023
Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study
Int J Drug Policy, 116, 104044
DOI 10.1016/j.drugpo.2023.104044, PubMed 37149914
Publications 2022
[Transjugular intrahepatic portosystemic shunt for portal hypertension]
Tidsskr Nor Laegeforen, 142 (14)
DOI 10.4045/tidsskr.21.0911, PubMed 36226423
Peer support in small towns: A decentralized mobile Hepatitis C virus clinic for people who inject drugs
Liver Int, 42 (6), 1268-1277
DOI 10.1111/liv.15266, PubMed 35362660
Publications 2021
Hepatitis C reinfection in former and active injecting drug users in Belgium
Harm Reduct J, 18 (1), 102
DOI 10.1186/s12954-021-00552-x, PubMed 34641896
Hepatitis C in Iceland: a milestone for global elimination
Lancet Gastroenterol Hepatol, 6 (8), 599-600
DOI 10.1016/S2468-1253(21)00182-5, PubMed 34171268
Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV)
PLoS Med, 18 (6), e1003653
DOI 10.1371/journal.pmed.1003653, PubMed 34061883
Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway
Int J Drug Policy, 96, 103165
DOI 10.1016/j.drugpo.2021.103165, PubMed 33642182
Publications 2020
Effect of gender on mortality and causes of death in cirrhotic patients with gastroesophageal varices. A retrospective study in Norway
PLoS One, 15 (3), e0230263
DOI 10.1371/journal.pone.0230263, PubMed 32163489
Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs
Trials, 21 (1), 524
DOI 10.1186/s13063-020-04434-8, PubMed 32539853
Publications 2019
Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV)
BMC Infect Dis, 19 (1), 943
DOI 10.1186/s12879-019-4598-7, PubMed 31703669
Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis
J Hepatol, 72 (4), 643-657
DOI 10.1016/j.jhep.2019.11.012, PubMed 31785345
The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination
Clin Infect Dis, 69 (12), 2218-2227
DOI 10.1093/cid/ciz714, PubMed 31352481
The relationship between IFNL4 genotype and the rate of fibrosis in hepatitis C patients
Scand J Gastroenterol, 54 (9), 1172-1175
DOI 10.1080/00365521.2019.1643403, PubMed 31479286
How can we achieve WHO's elimination target for hepatitis C incidence?
Lancet Gastroenterol Hepatol, 4 (6), 415-417
DOI 10.1016/S2468-1253(19)30120-7, PubMed 30981687
Publications 2018
Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework
Liver Int, 39 (1), 20-30
DOI 10.1111/liv.13949, PubMed 30157316
Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe
J Hepatol, 68 (3), 402-411
DOI 10.1016/j.jhep.2017.10.010, PubMed 29080808
Hepatitis C in drug addicts
Tidsskr. Nor. Laegeforen., 138 (13), 1243
[Elimination of hepatitis C is possible]
Tidsskr Nor Laegeforen, 138 (7)
DOI 10.4045/tidsskr.18.0099, PubMed 29663789
Elimination of Hepatitis C is possible
Tidsskr. Nor. Laegeforen., 138 (7), 630-633
Publications 2017
Increased hope following successful treatment for hepatitis C infection
J Adv Nurs, 74 (3), 724-733
DOI 10.1111/jan.13487, PubMed 29082540
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study
BMC Infect Dis, 17 (1), 420
DOI 10.1186/s12879-017-2517-3, PubMed 28610605
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs
Int J Drug Policy, 47, 51-60
DOI 10.1016/j.drugpo.2017.05.019, PubMed 28683982
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study
Int J Drug Policy, 47, 177-186
DOI 10.1016/j.drugpo.2017.05.020, PubMed 28624134
Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study
Int J Drug Policy, 47, 230-238
DOI 10.1016/j.drugpo.2017.05.040, PubMed 28633998
Publications 2016
Hepatitis C reinfection after sustained virological response
J Hepatol, 64 (5), 1020-1026
DOI 10.1016/j.jhep.2016.01.001, PubMed 26780289
Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study
PLoS One, 11 (11), e0166451
DOI 10.1371/journal.pone.0166451, PubMed 27846264
HCV epidemiology in high-risk groups and the risk of reinfection
J Hepatol, 65 (1 Suppl), S33-S45
DOI 10.1016/j.jhep.2016.07.012, PubMed 27641987
Publications 2010
Liver fibrosis in hepatitis C patients of Pakistani versus Scandinavian origin
Scand J Gastroenterol, 45 (12), 1503-8
DOI 10.3109/00365521.2010.510571, PubMed 20698740